EGFR and non-small cell lung carcinoma: In summary, for the first time, we report that ilV30, tlV20, and diagnosed COPD may predict the risk of symptomatic RP among NSCLC patients receiving EGFR-TKIs and conventionally fractionated TRT concurrently.